Disease relevance of Chromium monophosphate

• CONCLUSION: Intraperitoneal chromic phosphate did not decrease the risk of relapse or improve survival for patients with stage III epithelial ovarian cancer after a negative SLL [1].
• Organ culture of craniopharyngioma and its cellular effects induced by colloidal chromic phosphate [2].
• Work in progress: intra-arterial P-32 chromic phosphate for prevention of postoperative liver metastases in high-risk colorectal cancer patients [3].
• Eight patients with locally extensive colorectal cancer were treated with colloidal P-32 chromic phosphate via the superior mesenteric artery following resection to prevent development of liver metastases [3].
• Hemarthrosis and synovitis associated with hemophilia: clinical use of P-32 chromic phosphate synoviorthesis for treatment [4].

High impact information on Chromium monophosphate

• Since a marked clinical improvement has been reported following chromic phosphate treatment in recurrent craniopharyngioma, we have attempted to study the in vitro cellular changes of two craniopharyngiomas maintained in organ culture system and subsequently treated with colloidal chronic phosphate [2].
• PURPOSE: To evaluate the clinical usefulness of phosphorus-32 chromic phosphate synoviorthesis in patients with hemophilia, recurrent hemarthrosis, and synovitis [4].
• A 68-yr-old male with agnogenic myeloid metaplasia was given phosphorus-32-colloidal chromic phosphate intrapericardially for the treatment of malignant pericardial effusion [5].
• Phosphorus-32-colloidal chromic phosphate: treatment of choice for malignant pericardial effusion [5].
• METHODS AND MATERIALS: Three agents have been studied: 131I antiferritin monoclonal antibody, colloidal 32P chromic phosphate, and 131I transferrin [6].

Chemical compound and disease context of Chromium monophosphate

• The long-term outcome of patients with hemophilia who were treated with phosphate-32 chromic phosphate radiosynovectomy was evaluated [7].
• Intraperitoneal (IP) radioactive chromic phosphate (P32) remains investigational in the treatment of patients with ovarian and/or endometrial cancer [8].

Biological context of Chromium monophosphate

• The radiation effects of intra-articular injection of 0.25 mCi of 32P in the form of colloidal chromic phosphate were investigated in one of the knee joints of adult Wistar rats [9].

Anatomical context of Chromium monophosphate

• The measurement of radiation doses from P32 chromic phosphate therapy of the peritoneum using SPECT [10].
• Radioactivity in breast milk after intraperitoneal chromic phosphate for the treatment of early ovarian cancer [11].

Associations of Chromium monophosphate with other chemical compounds

• STUDY DESIGN: The radiobiologic effectiveness of bismuth 212 was compared in vitro to x rays and chromic phosphate phosphorus 32) [12].

Gene context of Chromium monophosphate

• CA-125 levels after surgical exploration and radioactive chromic phosphate in ovarian cancer patients [13].
• 32P-colloidal chromic phosphate was employed, with an average dose from 6 mCi for large joints (knees) to 0.3 mCi for small peripheral joints such as average dose from 6 mCi for large joints (knees) to 0.3 mCi for small peripheral joints such as the MCP or PIP joints [14].
• A calculated radiation dose of 5000 rads was delivered to the liver by injecting radioactive 32-P chromic phosphate colloid through the superior mesenteric and celiac arteries [15].

Analytical, diagnostic and therapeutic context of Chromium monophosphate

• Those at low risk require only surgery, whereas those at high risk should receive either IP radioactive chromic phosphate or systemic chemotherapy following surgery [16].
• Moreover, there was a total absence of complications with the use of the sequential steps of pretherapy peritoneoscopy, a normal preinjection peritoneogram, injection of chromic phosphate in large volumes of solution, frequent change of position of the patient after injection, and abdominal scans after injection [17].
• Among 8 patients treated with HMF and either intraperitoneal chromic phosphate and/or alternating platinum-based chemotherapy following second-look surgery which documented persistent carcinoma, 3 have experienced disease-free intervals of 19, 27, and 42 months [18].
• The distributions in mice of intraperitoneally injected 211At microspheres, 90Y silicate colloid, and 32P chromic phosphate colloid were compared [19].
• This report presents a case of colon perforation which occurred 4 months after treatment with intraperitoneal chromic phosphate for stage IB ovarian papillary serous cystadenocarcinoma [20].

References